Published in Expert Opin Biol Ther on April 01, 2008
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach. PLoS One (2015) 1.39
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother (2012) 1.01
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther (2011) 0.96
Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther (2010) 0.91
Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res (2009) 0.88
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PLoS One (2012) 0.86
Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther (2011) 0.86
Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice. BMC Cancer (2014) 0.84
Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine (2010) 0.82
Human papillomavirus vaccination: current indications and future directions. Obstet Gynecol Clin North Am (2013) 0.81
Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine (2010) 0.80
Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Gene Ther (2009) 0.80
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
HPV vaccine: Current status and future directions. Med J Armed Forces India (2015) 0.79
Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model. Int J Nanomedicine (2016) 0.79
Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. J Transl Med (2010) 0.78
A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. J Transl Med (2015) 0.77
Minute time scale prolyl isomerization governs antibody recognition of an intrinsically disordered immunodominant epitope. J Biol Chem (2013) 0.76
A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. Oncoimmunology (2016) 0.76
Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother (2014) 0.76
Mutagenic Potential ofBos taurus Papillomavirus Type 1 E6 Recombinant Protein: First Description. Biomed Res Int (2015) 0.75
Hepatitis C virus E2 protein encapsulation into poly d, l-lactic-co-glycolide microspheres could induce mice cytotoxic T-cell response. Int J Nanomedicine (2016) 0.75
Suppressive Effect of Constructed shRNAs against Apollon Induces Apoptosis and Growth Inhibition in the HeLa Cell Line. Iran Biomed J (2016) 0.75
The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res (2016) 0.75
Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana. PLoS One (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 7.07
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 2.59
Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell (2004) 2.46
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol (1998) 2.20
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother (2006) 2.20
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res (2001) 1.75
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors. J Virol (2000) 1.49
Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther (2003) 1.45
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res (2000) 1.32
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 1.25
Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol (2002) 1.24
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci (1998) 1.18
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses (1997) 1.16
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther (2004) 1.16
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res (2002) 1.15
Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol (2000) 1.14
Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines (2007) 1.14
An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol (2004) 1.13
Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res (2004) 1.13
Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res (2007) 1.12
Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res (2003) 1.12
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11
Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 1.10
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10
Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol (2000) 1.09
Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother (2000) 1.09
Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol (2001) 1.08
Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine (2000) 1.08
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther (2006) 1.08
Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology (2002) 1.06
Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res (2001) 1.06
Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun (2007) 1.06
Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol (2003) 1.05
Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine (2004) 1.04
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother (2004) 1.04
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol (2007) 1.03
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03
Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res (1998) 1.03
Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res (2005) 1.03
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother (2005) 1.01
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01
Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther (2005) 1.01
Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg (2004) 1.00
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol (2005) 1.00
A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci (2006) 1.00
Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther (2001) 1.00
HPV DNA vaccines. Front Biosci (2003) 0.98
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des (2005) 0.98
Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol (2002) 0.98
Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res (2000) 0.98
Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol (2007) 0.97
Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J Virol (2004) 0.96
Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol (2001) 0.96
Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. Mol Ther (2007) 0.96
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother (2012) 1.10
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08
A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther (2006) 1.08
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine (2007) 1.07
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother (2008) 1.04
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02
DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02
Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun (2008) 1.02
Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virol J (2007) 1.02
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther (2010) 1.01
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01
Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther (2005) 1.01
DNA vaccines for cancer. IDrugs (2003) 1.00
Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res (2010) 0.99
Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt (2010) 0.99
Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res (2012) 0.99
MR imaging findings of medulla oblongata involvement in posterior reversible encephalopathy syndrome secondary to hypertension. AJNR Am J Neuroradiol (2008) 0.98
HPV DNA vaccines. Front Biosci (2003) 0.98
Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol (2002) 0.98
Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. J Biomed Opt (2007) 0.98
In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell Biosci (2011) 0.97
Molecular epidemiology of human papillomavirus. J Formos Med Assoc (2008) 0.97
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther (2009) 0.97
CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther (2003) 0.97
Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene (2007) 0.96
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther (2011) 0.96
Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater (2013) 0.95
Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci (2005) 0.95
Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther (2008) 0.95
Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine (2011) 0.95
Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol (2009) 0.94
Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine (2008) 0.94
Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother (2013) 0.94
Immune mechanism of the antitumor effects generated by bortezomib. J Immunol (2012) 0.93
Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer (2007) 0.93
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92
Change in cerebral perfusion after carotid angioplasty with stenting is related to cerebral vasoreactivity: a study using dynamic susceptibility-weighted contrast-enhanced MR imaging and functional MR imaging with a breath-holding paradigm. AJNR Am J Neuroradiol (2009) 0.92
Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther (2009) 0.91